DEF 14A: Iterum Seeks Shareholder Nod for Capital Boost

Iterum Therapeutics plc calls for shareholder approval on critical proposals, including a significant increase in authorized share capital and an amended equity incentive plan, vital for future funding and ORLYNVAH commercialization.

Summary

• Iterum Therapeutics plc will hold its 2025 Annual General Meeting (AGM) on September 10, 2025, in Dublin, Ireland.
• Shareholders are asked to vote on nine proposals, including the re-election of a Class I director, ratification of KPMG as independent auditors, an advisory vote on named executive officer compensation, and key capital structure changes.
• The company seeks to increase its authorized share capital from $1,800,000 to $2,600,000 by creating an additional 80,000,000 ordinary shares.
• This capital increase, along with updated director allotment authority and pre-emption rights opt-out, is deemed crucial for future capital raises and general corporate purposes, including the commercialization of ORLYNVAH.
• As of March 31, 2025, the company reported cash and cash equivalents of $12.7 million, which are expected to fund operations only into 2026.
• The company's future viability beyond 2025 is explicitly stated as dependent on ORLYNVAH sales and the ability to raise additional capital.
• An amendment to the 2018 Equity Incentive Plan is proposed to increase the number of ordinary shares available for issuance by 4,000,000, bringing the total to 5,349,376 shares.
• The company's overhang (potential dilution) is currently 3.20% and would increase to 12.70% with the proposed equity plan amendment.
• The three-year average gross burn rate (2022-2024) for equity awards was 2.7%.

Sentiment

Score: 3

Explanation: The company is facing significant financial challenges, including consistent net losses and a stated 'substantial doubt about our ability to continue as a going concern' without further capital raises. While management is proactively seeking shareholder approvals to enable future financing and commercialization efforts for ORLYNVAH, the underlying financial health and reliance on future capital are major concerns. The need for these approvals highlights the precarious financial position.

Positives

• The Board of Directors unanimously recommends voting FOR all key proposals (1-7), indicating internal alignment on strategic direction.
• The company is actively preparing for the commercial launch of ORLYNVAH in the U.S. with its partner EVERSANA, aiming to address patient needs.
• Executive compensation programs are designed with a pay-for-performance philosophy, aligning management interests with shareholder value creation.
• The company has adopted robust corporate governance policies, including a Compensation Recovery Policy (Clawback Policy) and Anti-Hedging/Anti-Pledging Policies.
• The board has separated the Chairman and CEO roles, with an independent Chairman, to enhance oversight and independence from management.

Negatives

• The company reported significant net losses: $24.8 million in 2024, $38.4 million in 2023, and $44.4 million in 2022, indicating ongoing unprofitability.
• There is 'substantial doubt about our ability to continue as a going concern' beyond 2025 if the company cannot raise additional capital.
• Current authorized share capital limits the company's ability to issue new shares, with only 28,380,798 ordinary shares available as of June 30, 2025.
• The 2024 Rights Offering, a recent capital raise, was time-consuming (3.5 months) and costly (over $1.6 million in fees), highlighting inefficiencies due to Irish legal requirements.
• The company's current equity overhang of 3.20% is considered too low to be competitive in attracting and retaining top talent, potentially forcing increased cash compensation.

Risks

• Inability to raise additional capital to fund operations beyond 2025, which could severely limit the company's ability to continue as a going concern.
• Competitive disadvantage in capital raising compared to U.S.-incorporated, Nasdaq-listed peers due to Irish legal requirements for shareholder approval of share allotments and pre-emption rights.
• Potential for delay, reduction, or elimination of product development programs or ORLYNVAH commercialization if sufficient capital is not raised.
• Risk of share price decline due to investor loss of confidence if the company cannot secure necessary funding.
• Increased cash compensation expenses to retain critical talent if the proposed equity incentive plan amendment is not approved, further depleting financial resources.

Future Outlook

The company expects its current cash and cash equivalents to fund operations into 2026. Future viability beyond 2025 is dependent on potential sales of ORLYNVAH and the ability to raise additional capital, including through potential share issuances. The proposed share capital increase and related authorities are critical to providing the flexibility to continue funding operations and achieve business objectives, including the commercial launch of ORLYNVAH.

Management Comments

• Our board of directors unanimously recommends a vote FOR Proposal Nos. 1 through 7 as set forth in the proxy statement. (Corey N. Fishman, President and Chief Executive Officer)
• We hope that you will participate in the meeting by voting through acceptable means as described in this proxy statement as promptly as possible. Your vote is important – so please exercise your right. (Corey N. Fishman, President and Chief Executive Officer)
• Our board of directors believes that separating the duties of the chairman of the board from the duties of our chief executive officer enhances the boards oversight of, and independence from, management, while also allowing our chief executive officer to focus on our day-to-day business operations instead of board administration.
• Our growth strategy depends on our ability to research, develop, and commercialize our product candidates, which requires significant capital.
• Our board of directors and management rely heavily on having the flexibility to quickly take advantage of opportunities to raise capital through share issuances for cash.
• The compensation committee believes that overhang of between 10-20% is required to make the Company competitive against its peer group of companies in terms of retaining key talent and providing market-competitive grants to the key talent to bring them in line with their peers, based on its review of publicly available data from its peer firms and others that it competes with for talent.

Industry Context

The company operates in the pharmaceutical industry, specifically focusing on product development and commercialization (ORLYNVAH). Its need for significant capital and reliance on equity financing is common for pre-revenue or early-stage biopharmaceutical companies. The discussion around Irish vs. U.S. capital market practices highlights the unique challenges Irish-incorporated, U.S.-listed companies face in capital raising compared to their U.S. peers, particularly regarding statutory pre-emption rights and the need for frequent shareholder approvals for share issuances.

Comparison to Industry Standards

• The proposed 100% increase to existing authorized share capital ranks within the 50th percentile compared to a peer group of 41 companies in 2024 and 2025.
• The company believes adhering to Irish market practices for share issuance limitations (e.g., 33% for allotment, 10% for pre-emption opt-out) would disadvantage it relative to U.S.-incorporated, U.S.-listed peers, as U.S. companies generally do not require shareholder approval for such renewals and do not grant pre-emptive rights on new issuances for cash.
• The company's current equity overhang of 3.20% is considered too low to be competitive in retaining and incentivizing top talent, with management believing a 10-20% overhang is competitive for its peer group.
• The three-year average gross burn rate of 2.7% is below what management believes is an appropriate burn rate to be competitive against peers in offering equity compensation.

Management Changes

Corporate Governance

Related Party Transactions

• Certain directors and affiliates participated in the 2024 Rights Offering, purchasing 436,794 Units for an aggregate of $528,520.74 (Corey N. Fishman: $99,961.73; Michael W. Dunne: $128,558.87; New Leaf Ventures III, L.P.: $220,768.13; New Leaf Biopharma Opportunities II, L.P.: $79,232.01).
• A consulting agreement with Dr. Michael W. Dunne (former Chief Scientific Officer and current director) provides for $5,000 per month for strategic advice related to oral sulopenem NDA resubmission; $60,000 was expensed in 2024 and $31,804 in 2025 as of July 1.
• A consulting agreement with Dr. Sailaja Puttagunta (former Chief Medical Officer) provides for $400 per hour for NDA support; $100,400 was expensed in 2024 and $19,200 in 2025 as of July 1.
• The company has entered into indemnification agreements with each of its directors and executive officers.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances but also stand to benefit if capital raises enable successful ORLYNVAH commercialization and improve company value.
• Employees and management are directly impacted by the proposed amendment to the equity incentive plan, which aims to enhance the company's ability to attract, retain, and motivate talent.
• Customers (patients) are expected to benefit from the successful commercialization of ORLYNVAH, which aims to provide treatment options for unmet medical needs.
• Creditors were impacted by the repayment of $11.1 million in principal and $3.6 million in accrued interest on Exchangeable Notes on January 31, 2025.

Next Steps

• Hold the 2025 Annual General Meeting on September 10, 2025, for shareholder votes on proposed resolutions.
• Proceed with the commercial launch of ORLYNVAH in the United States with commercialization partner EVERSANA.
• Pursue potential future capital raises to fund operations beyond 2025, contingent on shareholder approvals.
• If the 2018 Equity Incentive Plan amendment is approved, register the additional shares by filing a Registration Statement on Form S-8.

Key Dates

Recommendation

The company explicitly states 'substantial doubt about our ability to continue as a going concern' beyond 2025 without significant additional capital. While the proposed capital structure changes are necessary steps to enable future financing, the current financial position with consistent net losses and limited cash reserves presents a high-risk profile. The reliance on future ORLYNVAH sales, which may never achieve substantial positive cash flows, adds to the uncertainty. Investors should consider the significant dilution risk from potential future equity raises and the fundamental going concern warning.

Keywords

Iterum Therapeutics, SEC filing, Proxy Statement, Annual General Meeting, Share Capital Increase, Equity Incentive Plan, ORLYNVAH, Pharmaceutical, Biotech, Corporate Governance, Capital Raise, Going Concern, Shareholder Vote, Executive Compensation, Risk Management